Targeting the DNA damage response to reshape the tumor immune microenvironment
This review summarizes the major DDR pathways, their roles in tumor evolution and immune remodeling, and the rationale and limitations of combining DDR-targeted therapies with immunotherapy and discusses biomarker refinement, resistance mechanisms, and future strategies for translating genomic stress into durable antitumor responses.